Nature of Business (Details)			12 Months Ended
	Feb. 10, 2023	Feb. 09, 2023 shares	Dec. 31, 2022 USD ($) segment	Dec. 31, 2021 USD ($)	Mar. 24, 2023 USD ($)	Aug. 13, 2021 USD ($)	Dec. 31, 2020 USD ($)
Nature of business:
Number of operating segments | segment			2
Accumulated deficit			$ (219,563,446)	$ (205,765,107)
Net loss			(13,798,339)	(12,550,973)
Net cash used in operating activities			(12,649,021)	(11,739,620)
Cash and cash equivalents			13,359,615	26,043,897			$ 18,676,663
Net decrease in cash			$ 12,684,282	(7,367,234)
Percentage change in cash and cash equivalent			49.00%
Accumulated deficit			$ 219,563,446	205,765,107
Working capital			2,663,721	20,278,345
Working capital increase, decrease			2,663,721	$ (22,942,066)
Working capital increase (decrease) as a percent				113.00%
Government grant funding			115,130	$ 138,889
Fractional shares issue under reverse stock split | shares		0
Subsequent Event [Member]
Nature of business:
Reverse stock spilt effective from February 10, 2023	0.067	0.067
CiVax
Nature of business:
Revenue from collaborative arrangement			$ 1,500,000
Term (in years)			two years
HyBryte
Nature of business:
Revenue from collaborative arrangement			$ 1,100,000
Term (in years)			four years
NIH
Nature of business:
Government grant funding			$ 1,700,000
DTRA | Contract revenue
Nature of business:
Revenue from collaborative arrangement			$ 600,000
Term (in years)			three years
B Riley Sales Agreement [Member]
Nature of business:
Common Stock, Value, Subscriptions						$ 26,600,000
B Riley Sales Agreement [Member] | Subsequent Event [Member]
Nature of business:
Common Stock, Value, Subscriptions					$ 6,600,000